Chelsea Therapeutics International R&D Expense Quarterly:

1.957M for March 31, 2013
View Full Chart

Chelsea Therapeutics International R&D Expense Quarterly Chart

    Chelsea Therapeutics International Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 1.957M
    Dec. 31, 2012 0.8703M
    Sept. 30, 2012 2.480M
    June 30, 2012 4.696M
    March 31, 2012 8.699M
    Dec. 31, 2011 7.713M
    Sept. 30, 2011 7.418M
    June 30, 2011 10.68M
    March 31, 2011 11.46M
    Dec. 31, 2010 10.17M
    Sept. 30, 2010 7.425M
    June 30, 2010 8.394M
    March 31, 2010 4.880M
    Dec. 31, 2009 4.025M
    Sept. 30, 2009 5.357M
    June 30, 2009 8.096M
    March 31, 2009 6.507M
    Dec. 31, 2008 7.194M
       
    Sept. 30, 2008 7.041M
    June 30, 2008 6.369M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Jan. 31, 2005 Go Pro
    Oct. 31, 2004 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    CHTP R&D Expense Quarterly Benchmarks

    Companies
    BioDelivery Sciences International 11.56M
    Cempra 7.371M
    Achillion Pharmaceuticals 8.719M

    CHTP R&D Expense Quarterly Rankings

    Overall 86th percentile
    1107 of 8002
    Sector 50th percentile
    338 of 684 in Healthcare
    Industry 38th percentile
    153 of 248 in Biotechnology

    CHTP R&D Expense Quarterly Range, Past 5 Years

    Minimum 0.8703M Dec 2012
    Maximum 11.46M Mar 2011
    Average 6.572M